• Dr. Alvira Macanovic outlines the benefits of using AI to overcome sparse data and transform ultrasound images into MRI-quality heart images

Toronto, Ontario — January 3, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF), now bringing its AI-powered heart-scanning technology to the world’s hospitals, is delighted to release a comprehensive white paper, authored by Dr. Alvira Macanovic, the CEO and President of the company, Cristina Almeida, BScKin (Hons.), RDCS AE, PE (Clinical Applications Lead), and Desmond Hirson, MEng (Technology Advisor).

The white paper outlining the proven reliability of Ventripoint’s AI-powered technology to turn ultrasounds into MRI-quality images of the heart is being distributed to current and future partners. It has also been published by Canada Health Watch, a media platform covering advances in health care.

Dr. Macanovic's white paper focuses on a long-standing challenge in cardiac ultrasound: how to achieve clear and accurate imaging of the heart, particularly the right ventricle (RV)? Traditional methods like two-dimensional echocardiography (2DE) have been limited in their ability to accurately measure chamber size and function due to imaging complexities.

Ventripoint’s AI technology augments sparse data from ultrasounds by tapping into a vast library of cardiac MRI images, resulting in MRI-quality images that previously were not reliably attainable.

“The purpose of our white paper is to indicate to cardiologists and hospital administrators that Ventripoint’s technology has solved this problem and is a reliable diagnostic tool transforming ultrasound scans into MRI-quality images of the heart,” said Dr. Macanovic. “We are not trying to replace MRIs, but we can augment patient and physicians’ access to heart scans at a fraction of the time and cost of an MRI, improving health outcomes as well as saving hospital and clinical resources.”

Central to this white paper is the VMS+ Knowledge-Based Reconstruction Algorithm, an AI-driven innovation advanced under the oversight of Dr. Macanovic, a Ph.D. who has focused on designing and developing medical devices, with nearly 20 years in medical technology commercialization.

With Ventripoint’s AI technology — now being commercialized and used in hospitals and clinics — only a small number of predefined anatomical points from ultrasound images are required to generate accurate heart measurements, offering precision on par with cardiac MRI (cMRI) scans.

This novel approach brings multiple advantages. It surpasses traditional imaging methods in accuracy and speed. With the VMS+ system, echo scans are cheaper and quicker than cMRI, enabling more widespread and routine cardiac monitoring, crucial for early detection and intervention in heart conditions.

The practical application of the VMS+ system, which is constantly being upgraded, has been validated through its consistent and reliable performance, making it a new tool for accurate diagnosis and treatment in cardiac care. This is especially significant in regions where advanced imaging technologies like cMRI are less accessible.

For further information, please contact:

Jonathan Robinson CFA

This email address is being protected from spambots. You need JavaScript enabled to view it.

(416) 669-1001

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.